2318 lines
218 KiB
Text
2318 lines
218 KiB
Text
<!DOCTYPE html>
|
||
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
|
||
<head>
|
||
<meta charset="utf-8" />
|
||
<noscript><meta http-equiv="Refresh" content="0; URL=/big_pipe/no-js?destination=/funding/awarded%3Fpage%3D4%26research_program%3D146" />
|
||
</noscript><meta name="description" content="View all awarded funding as part of the NIH HEAL (Helping to End Addiction Long-term) Initiative." />
|
||
<link rel="canonical" href="https://heal.nih.gov/funding/awarded" />
|
||
<link rel="image_src" href="/files/heal-logo-social.png" />
|
||
<meta property="og:site_name" content="NIH HEAL Initiative" />
|
||
<meta property="og:type" content="website" />
|
||
<meta property="og:url" content="https://heal.nih.gov/funding/awarded" />
|
||
<meta property="og:title" content="Awarded Funding" />
|
||
<meta property="og:description" content="Learn about the research supported by the HEAL Initiative by exploring the database of funded awards." />
|
||
<meta property="og:image" content="https://heal.nih.gov/files/heal-logo-social.png" />
|
||
<meta property="og:image:url" content="https://heal.nih.gov/files/heal-logo-social.png" />
|
||
<meta property="og:updated_time" content="Thu, 09/21/2023 - 7:31am" />
|
||
<meta property="article:published_time" content="Fri, 09/06/2019 - 2:20pm" />
|
||
<meta property="article:modified_time" content="Thu, 09/21/2023 - 7:31am" />
|
||
<meta name="twitter:card" content="summary_large_image" />
|
||
<meta name="twitter:description" content="Learn about the research supported by the HEAL Initiative by exploring the database of funded awards." />
|
||
<meta name="twitter:title" content="Awarded Funding" />
|
||
<meta name="twitter:creator" content="@NIH" />
|
||
<meta name="twitter:image" content="https://heal.nih.gov/files/heal-logo-social.png" />
|
||
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
|
||
<meta name="MobileOptimized" content="width" />
|
||
<meta name="HandheldFriendly" content="true" />
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
|
||
<link rel="icon" href="/files/favicon.ico" type="image/vnd.microsoft.icon" />
|
||
<link rel="alternate" type="text/csv" title="All - Awarded Export" href="https://heal.nih.gov/funding/awarded/export?research_program=146&page&_format=csv" />
|
||
<script>window.a2a_config=window.a2a_config||{};a2a_config.callbacks=[];a2a_config.overlays=[];a2a_config.templates={};</script>
|
||
|
||
<title>Funded Projects | NIH HEAL Initiative</title>
|
||
<link rel="stylesheet" media="all" href="/files/css/css_Xd0pI9rakjfnp2UWa-7weru_1kc-L_azTnBAZQ1TLSs.css?delta=0&language=en&theme=particle&include=eJxFzm0OwyAIBuALoR6poYVNN_wI6trefnHR7A-BB0JeJGoZ0-1wNvahOTU4srIj7QXF4gsvoHwmyUibhPTeBHcWVrfUDDVTTfMcGfhqQ9eXOUJBxadi8XVt_mJ7Kn2XUD3TOGzhEHYjC9S7No5ux8rwCXxW96s2ZurCX0opTZs" />
|
||
<link rel="stylesheet" media="all" href="/files/css/css_Kzcx5y8_UgmvOm2su6202zfZz3qqdNhdBCeZjOratTU.css?delta=1&language=en&theme=particle&include=eJxFzm0OwyAIBuALoR6poYVNN_wI6trefnHR7A-BB0JeJGoZ0-1wNvahOTU4srIj7QXF4gsvoHwmyUibhPTeBHcWVrfUDDVTTfMcGfhqQ9eXOUJBxadi8XVt_mJ7Kn2XUD3TOGzhEHYjC9S7No5ux8rwCXxW96s2ZurCX0opTZs" />
|
||
|
||
<link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin="anonymous">
|
||
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/solid.min.css">
|
||
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/brands.min.css">
|
||
<link href="https://fonts.googleapis.com/css?family=Montserrat:400,600,700&display=swap" rel="stylesheet">
|
||
<!-- Global site tag (gtag.js) - Google Analytics -->
|
||
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-147034615-1"></script>
|
||
<meta name="msvalidate.01" content="C17405549FB53FD60915A09433C78FF3" />
|
||
<meta http-equiv="X-UA-Compatible" content="IE=EmulateIE8"><script type="text/javascript">(window.NREUM||(NREUM={})).init={ajax:{deny_list:["bam.nr-data.net"]}};(window.NREUM||(NREUM={})).loader_config={licenseKey:"4885254293",applicationID:"336795922"};;/*! For license information please see nr-loader-rum-1.283.2.min.js.LICENSE.txt */
|
||
(()=>{var e,t,r={122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},217:(e,t,r)=>{"use strict";r.d(t,{D0:()=>m,gD:()=>v,xN:()=>h});r(860).K7.genericEvents;const n="experimental.marks",i="experimental.measures",o="experimental.resources",a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var s=r(614),c=r(944),u=r(384),l=r(122);const d="[data-nr-mask]",f=()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(n)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(i)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(o)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:s.wk,inactiveMs:s.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(d):""===t||null===t?e.mask_selector=d:(0,c.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,c.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,c.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}},g={},p="All configuration objects require an agent identifier!";function m(e){if(!e)throw new Error(p);if(!g[e])throw new Error("Configuration for ".concat(e," was never set"));return g[e]}function h(e,t){if(!e)throw new Error(p);g[e]=(0,l.a)(t,f());const r=(0,u.nY)(e);r&&(r.init=g[e])}function v(e,t){if(!e)throw new Error(p);var r=m(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>d});var n=r(122),i=r(384),o=r(154),a=r(324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0,harvester:void 0},l={};function d(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!l[e])throw new Error("Runtime for ".concat(e," was never set"));return l[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");l[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(l[e],"harvestCount")||Object.defineProperty(l[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=l[e])}},324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,xv:()=>n});const n="1.283.2",i="PROD",o="CDN"},154:(e,t,r)=>{"use strict";r.d(t,{OF:()=>c,RI:()=>i,WN:()=>l,bv:()=>o,gm:()=>a,mw:()=>s,sb:()=>u});var n=r(863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s=Boolean("hidden"===a?.document?.visibilityState),c=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),u=c&&"undefined"==typeof SharedWorker,l=((()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);Array.isArray(e)&&e.length>=2&&e[1]})(),Date.now()-(0,n.t)())},687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>d,x3:()=>u});var n=r(836),i=r(606),o=r(860),a=r(646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};l(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),g(e,t,!1),s[e].size&&f(e))}function l(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function d(e="",t="feature",r=!1){if(l(e),!e||!s[e].get(t)||r)return g(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),g(e,t)})))}function g(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(990),o=r(371),a=r(646),s=r(607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},l={},d=!1;try{d=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=g(n),c=m(e),l=c.length,d=0;d<l;d++)c[d].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:h,listeners:m,context:g,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:d?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:d};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function g(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=m(e).concat(t)}function m(e){return n[e]||[]}function h(t){return l[t]=l[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),l=(0,n.Zm)();l.ee||(l.ee=u)},646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(566).bz)()},566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,bz:()=>a});var n=r(154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}},614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},284:(e,t,r)=>{"use strict";r.d(t,{t:()=>c,B:()=>s});var n=r(836),i=r(154);const o="newrelic";const a=new Set,s={};function c(e,t){const r=n.ee.get(t);s[t]??={},e&&"object"==typeof e&&(a.has(t)||(r.emit("rumresp",[e]),s[t]=e,a.add(t),function(e={}){try{i.gm.dispatchEvent(new CustomEvent(o,{detail:e}))}catch(e){}}({loaded:!0})))}},990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>l,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>d});var n=r(154),i=r(863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function l(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(836),i=r(607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];l(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,d;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],l],e)}i(r+"start",[o,a,s],l,c);try{return d=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],l,c),e}finally{i(r+"end",[o,a,d],l,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},a="log";n.K7.logging},773:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>s,TZ:()=>n,rs:()=>i,xV:()=>a});r(154),r(566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},344:(e,t,r)=>{"use strict";r.d(t,{G4:()=>i});var n=r(614);r(860).K7.sessionReplay;const i={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"};n.g.ERROR,n.g.FULL,n.g.OFF},234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(836),i=r(687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},603:(e,t,r)=>{"use strict";r.d(t,{j:()=>K});var n=r(860),i=r(555),o=r(371),a=r(908),s=r(836),c=r(687),u=r(289),l=r(154),d=r(944),f=r(773),g=r(384),p=r(344);const m=["setErrorHandler","finished","addToTrace","addRelease","recordCustomEvent","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],h=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(863),b=r(614),y=r(993);var w=r(646),R=r(434);const A=new Map;function E(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,d.R)(29);const i=function(e){return(e||s.ee).get("logger")}(e),o=(0,R.YM)(i),a=new w.y(s.P);a.level=n.level,a.customAttributes=n.customAttributes;const c=t[r]?.[R.Jt]||t[r];return A.set(c,a),o.inPlace(t,[r],"wrap-logger-",(()=>A.get(c))),i}function _(){const e=(0,g.pV)();m.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,d.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const x={};function N(e,t,g=!1){t||(0,c.Ak)(e,"api");const m={};var w=s.ee.get(e),R=w.get("tracer");x[e]=b.g.OFF,w.on(p.G4.REPLAY_RUNNING,(t=>{x[e]=t}));var A="api-",_=A+"ixn-";function N(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),j(A,n,!0,o||null===r?"session":void 0)(t,r)}function k(){}m.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,w),function(e,t,r={},i=y.p_.INFO){(0,a.p)(f.xV,["API/logging/".concat(i.toLowerCase(),"/called")],void 0,n.K7.metrics,e),(0,a.p)(y.ET,[(0,v.t)(),t,r,i],void 0,n.K7.logging,e)}(w,e,t,r)},m.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,w),E(w,e,t,{customAttributes:r,level:i})},h.forEach((e=>{m[e]=j(A,e,!0,"api")})),m.addPageAction=j(A,"addPageAction",!0,n.K7.genericEvents),m.recordCustomEvent=j(A,"recordCustomEvent",!0,n.K7.genericEvents),m.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,j(A,"setPageViewName",!0)()},m.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return N(e,t,"setCustomAttribute",r);(0,d.R)(40,typeof t)}else(0,d.R)(39,typeof e)},m.setUserId=function(e){if("string"==typeof e||null===e)return N("enduser.id",e,"setUserId",!0);(0,d.R)(41,typeof e)},m.setApplicationVersion=function(e){if("string"==typeof e||null===e)return N("application.version",e,"setApplicationVersion",!1);(0,d.R)(42,typeof e)},m.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,w),w.emit("manual-start-all")}catch(e){(0,d.R)(23,e)}},m[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,w),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,w)},m[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,w),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,w)},m.interaction=function(e){return(new k).get("object"==typeof e?e:{})};const T=k.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,w),g||(0,a.p)(_+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,w),function(){if(R.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw R.emit("fn-err",[arguments,this,t],r),t}finally{R.emit("fn-end",[(0,v.t)()],r)}}}};function j(e,t,r,i){return function(){return(0,a.p)(f.xV,["API/"+t+"/called"],void 0,n.K7.metrics,w),i&&(0,a.p)(e+t,[r?(0,v.t)():performance.now(),...arguments],r?null:this,i,w),r?void 0:this}}function I(){r.e(296).then(r.bind(r,778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,d.R)(27,e),w.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{T[e]=j(_,e,void 0,g?n.K7.softNav:n.K7.spa)})),m.setCurrentRouteName=g?j(_,"routeName",void 0,n.K7.softNav):j(A,"routeName",!0,n.K7.spa),m.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,w),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!x[e]],void 0,n.K7.jserrors,w)},l.RI?(0,u.GG)((()=>I()),!0):I(),m}var k=r(217),T=r(122);const j={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},I={};var O=r(284);const S=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let P=!1;function K(e,t={},r,n){let{init:a,info:c,loader_config:u,runtime:d={},exposed:f=!0}=t;d.loaderType=r;const p=(0,g.pV)();c||(a=p.init,c=p.info,u=p.loader_config),(0,k.xN)(e.agentIdentifier,a||{}),function(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");I[e]=(0,T.a)(t,j);const r=(0,g.nY)(e);r&&(r.loader_config=I[e])}(e.agentIdentifier,u||{}),c.jsAttributes??={},l.bv&&(c.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,c);const m=(0,k.D0)(e.agentIdentifier),h=[c.beacon,c.errorBeacon];P||(m.proxy.assets&&(S(m.proxy.assets),h.push(m.proxy.assets)),m.proxy.beacon&&h.push(m.proxy.beacon),_(),(0,g.US)("activatedFeatures",O.B),e.runSoftNavOverSpa&&=!0===m.soft_navigations.enabled&&m.feature_flags.includes("soft_nav")),d.denyList=[...m.ajax.deny_list||[],...m.ajax.block_internal?h:[]],d.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,d),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=N(e.agentIdentifier,n,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=f),P=!0}},374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>u,K7:()=>s,P3:()=>c,XX:()=>i,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},c={[s.pageViewEvent]:1,[s.pageViewTiming]:2,[s.metrics]:3,[s.jserrors]:4,[s.spa]:5,[s.ajax]:6,[s.sessionTrace]:7,[s.softNav]:8,[s.sessionReplay]:9,[s.logging]:10,[s.genericEvents]:11},u={[s.pageViewEvent]:a,[s.pageViewTiming]:n,[s.ajax]:n,[s.spa]:n,[s.softNav]:n,[s.metrics]:i,[s.jserrors]:i,[s.sessionTrace]:o,[s.sessionReplay]:o,[s.logging]:"browser/logs",[s.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>"nr-rum-1.283.2.min.js",i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.283.2.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),l=0;l<u.length;l++){var d=u[l];if(d.getAttribute("src")==r||d.getAttribute("data-webpack")==t+o){s=d;break}}if(!s){c=!0;var f={296:"sha512-2Y8GMAOGF658KnXzOZ/v+DlLch8TBFvV0tTNnOy9wrpvtDa1t5CdZMyX+LubTymBlzPp6NUjllBghMCZqXBPmg=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var g=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(g.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=g.bind(null,s.onerror),s.onload=g.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={374:0,840:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.283.2.PROD"]=self["webpackChunk:NRBA-1.283.2.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(374);var e=i(944),t=i(344),r=i(566);class n{agentIdentifier;constructor(){this.agentIdentifier=(0,r.LA)(16)}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}recordCustomEvent(e,t){return this.#e("recordCustomEvent",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(217);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var l=i(603);var d=i(687),f=i(234),g=i(289),p=i(154),m=i(384);const h=e=>p.RI&&!0===(0,s.gD)(e,"privacy.cookies_enabled");function v(e){return!!(0,m.dV)().o.MO&&h(e)&&!0===(0,s.gD)(e,"session_trace.enabled")}var b=i(389);class y extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,d.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,b.J)((()=>{(0,d.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if(h(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(296).then(i.bind(i,861));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,o))return(0,d.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(296).then(i.bind(i,103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),t.runtime.harvester.initializedAggregates.push(this.featAggregate),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,d.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,g.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return v(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var w=i(630);class R extends y{static featureName=w.T;constructor(e,t=!0){super(e,w.T,t),this.importAggregator(e)}}var A=i(908),E=i(843),_=i(878),x=i(782),N=i(863);class k extends y{static featureName=x.T;constructor(e,t=!0){super(e,x.T,t),p.RI&&((0,E.u)((()=>(0,A.p)("docHidden",[(0,N.t)()],void 0,x.T,this.ee)),!0),(0,_.sp)("pagehide",(()=>(0,A.p)("winPagehide",[(0,N.t)()],void 0,x.T,this.ee))),this.importAggregator(e))}}var T=i(773);class j extends y{static featureName=T.TZ;constructor(e,t=!0){super(e,T.TZ,t),this.importAggregator(e)}}new class extends o{constructor(t){super(),p.gm?(this.features={},(0,m.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(R),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,l.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,m.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[R,k,j],loaderType:"lite"})})()})();</script>
|
||
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
|
||
<script>
|
||
window.dataLayer = window.dataLayer || [];
|
||
function gtag(){dataLayer.push(arguments);}
|
||
gtag('js', new Date());
|
||
|
||
gtag('config', 'UA-147034615-1');
|
||
</script>
|
||
|
||
<!-- Google Tag Manager -->
|
||
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
||
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
||
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
||
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
||
})(window,document,'script','dataLayer','GTM-W8TVZ6J');</script>
|
||
<!-- End Google Tag Manager -->
|
||
|
||
<!-- DAP -->
|
||
<script language="javascript" id="_fed_an_ua_tag" src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&subagency=NIH&exts=doc,docx,xls,xlsx,xlsm,ppt,pptx,exe,zip,pdf,js,txt,csv,dxf,wmv,jpg,wma,mov,avi,mp3,mp4,csv"></script>
|
||
|
||
<!-- End DAP -->
|
||
</head>
|
||
<body class="fout-fix" data-spy="scroll" data-target="#scrollnav">
|
||
<a href="#main-content" class="visually-hidden focusable">
|
||
Skip to main content
|
||
</a>
|
||
<!-- Google Tag Manager (noscript) -->
|
||
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W8TVZ6J"
|
||
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
|
||
<!-- End Google Tag Manager (noscript) -->
|
||
|
||
|
||
<div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
|
||
<div class="mobile-overlay" id="overlay" aria-hidden="true"></div>
|
||
|
||
<div id="header-container" class="header-container">
|
||
|
||
<div class="ribbon fluid-container">
|
||
<div class="container">
|
||
<div class="row">
|
||
<div class="col-sm-12">
|
||
|
||
<div class="ribbon-links">
|
||
<a href="http://www.hhs.gov/" class="">
|
||
<img src="/assets/hhs-logo.png" alt="U.S. Department of Health & Human Services website"/>
|
||
U.S. Department of Health & Human Services
|
||
</a>
|
||
<img src="/assets/delimiter-arrow.png" alt="" role="presentation"/>
|
||
<a href="https://www.nih.gov/">National Institutes of Health</a>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<div class="layout-container">
|
||
<header class="container navbar navbar-light navbar">
|
||
<div class="navbar-header-btns">
|
||
<button class="menu-btn" type="button" class="" aria-expanded="false">Menu</button>
|
||
<button class='searchBtnMobile' aria-label="search-toggle"></button>
|
||
|
||
</div>
|
||
<a href="/" class="navbar-logo gtm-header-home" title="Navbar Logo Title"><img src="../../../assets/NIH_HEAL_Color.svg" alt="Navbar Logo Alt"></a>
|
||
<form class="search-menu form-inline d-lg-block" action="https://search.usa.gov/search" accept-charset="UTF-8" method="get">
|
||
<input name="utf8" type="hidden" value="✓">
|
||
<input type="hidden" name="affiliate" id="affiliate" value="heal">
|
||
<div class="input-group">
|
||
<input class="search-input form-control" type="search" placeholder="Search" aria-label="Search heal.nih.gov" name="query">
|
||
<div class="input-group-append">
|
||
<button type="submit" class="btn btn gtm-header-search btn-tertiary">Search</button>
|
||
</div>
|
||
</div>
|
||
</form>
|
||
|
||
|
||
|
||
|
||
<nav role="navigation" aria-labelledby="block-particle-mainnavigation-menu" class="container navbar navbar-expand-lg navbar-light primary-navigation">
|
||
|
||
|
||
|
||
<h2 class="visually-hidden" id="block-particle-mainnavigation-menu">Main navigation</h2>
|
||
|
||
|
||
|
||
|
||
<ul class="no-bullets menu-level-0">
|
||
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-0">
|
||
<a href="/about" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/43151">About</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="no-bullets menu-level-1">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/why-heal" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/43131">Why HEAL?</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/opioid-crisis" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/43136">The Opioid Crisis</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/impact" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/42501">Making a Difference</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/nih-heal-initiative-leadership" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/43146">NIH HEAL Initiative Leadership</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/nih-heal-initiative-annual-report-budget" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/43141">Annual Report and Budget</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/about/strategic-plan" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/46921">Strategic Planning</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-0">
|
||
<a href="/research" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/16">Research</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-1 no-bullets">
|
||
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/research-to-practice" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/61">Translation of Research to Practice for the Treatment of Opioid Addiction</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="no-bullets menu-level-2">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/brim" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/106">Behavioral Research to Improve Medication-Based Treatment</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/continuum-care-hospitalized-patients-opioid-use-disorder" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42151">The Continuum of Care in Hospitalized Patients with Opioid Use Disorder and Infectious Complications of Drug Use</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/enhancing-clinical-trials-network" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/96">Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/harm-reduction-approaches-reduce-overdose-deaths" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/41416">Harm Reduction Research Network</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/healing-communities" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/91">HEALing Communities Study</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/delivery-healthcare-services-polysubstance-use" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42146">Improving Delivery of Healthcare Services for Polysubstance Use</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/jcoin" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/101">Justice Community Opioid Innovation Network</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/native-collective-research-effort-enhance-wellness-overdose-substance-mental-health-pain" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42586">Native Collective Research Effort to Enhance Wellness (N CREW) Program: Addressing Overdose, Substance Use, Mental Health, and Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/optimizing-addiction-services" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44086">Optimizing the Quality, Reach, and Impact of Addiction Services</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/research-to-practice/research-recovery-network" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/39646">Recovery Research Networks</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/new-strategies" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/66">New Strategies to Prevent and Treat Opioid Addiction</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/care-polysubstance-use-primary-care" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42126">Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/optimizing-care" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/111">Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/duration-retention-discontinuation" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/126">Optimizing the Duration, Retention, and Discontinuation of Medication Treatment for Opioid Use Disorder</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/preventing-opioid-use-disorder" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/116">Preventing Opioid Use Disorder</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/prevent-progression" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/131">Prevention of Progression to Moderate or Severe Opioid Use Disorder</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/new-strategies/sleep-dysfunction" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/121">Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/infants-and-children" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/71">Enhanced Outcomes for Infants and Children Exposed to Opioids</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/infants-and-children/act-now" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/136">Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/infants-and-children/opioid-exposure-during-pregnancy" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44096">The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/infants-and-children/healthy-brain" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/141">HEALthy Brain and Child Development Study (HBCD)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/infants-and-children/virtual-assessments-developmental-trajectories" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44101">Virtual Assessments to Understand Developmental Trajectories of Substance Use Exposure</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/therapeutic-options" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/76">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/therapeutic-options/immunotherapies" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/151">Development of Novel Immunotherapeutics for Opioid Addiction</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/therapeutic-options/focusing-development" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/146">Focusing Medication Development to Prevent and Treat Opioid Use Disorders and Overdose</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/therapeutic-options/oral-complications-buprenorphine" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44106">Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/therapeutic-options/rapid-assessment-emerging-opioid-threats" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44111">Rapidly Assessing the Public Health Impact of Emerging Opioid Threats</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/clinical-research" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/81">Clinical Research in Pain Management</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/health-equity-pain-management" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42106">Advancing Health Equity in Pain Management</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/pain-signatures" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/186">Acute to Chronic Pain Signatures Program</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/back-pain" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/161">Back Pain Consortium Research Program</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/biomarkers" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/191">Discovery and Validation of Biomarkers, Endpoints and Signatures for Pain Conditions</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/eppic-net" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/176">Early Phase Pain Investigation Clinical Network (EPPIC-Net)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/hemodialysis" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/181">Integrated Approach to Pain and Opioid Use in Hemodialysis Patients</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/pain-management-research" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/166">Pain Management Effectiveness Research Network</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/prism" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/171">Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/chronic-pain-rural-populations" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44091">Prevention and Management of Chronic Pain in Rural Populations</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/clinical-research/integrative-management-chronic-pain" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/39621">Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL)</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/preclinical-translational" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/86">Preclinical and Translational Research in Pain Management</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/optimization-non-addictive-therapies" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/206">Development and Optimization of Non-Addictive Therapies to Treat Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/novel-targets" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/216">Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/integrated-research" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/44116">Integrated Basic and Clinical Team-Based Research in Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/screening-platform" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/211">Preclinical Screening Platform for Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/restoring-joint-health-function-reduce-pain" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42136">Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN)</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/discoveries-into-devices" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/201">Translating Discoveries into Effective Devices to Treat Pain</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/preclinical-translational/novel-drugs-screening-platforms" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/196">Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-1">
|
||
<a href="/research/cross-cutting-research" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/40331">Cross-Cutting Research</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-2 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/cross-cutting-research/real-time-opioid-pain-management-data" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42116">Leveraging Existing and Real-Time Opioid and Pain Management Data </a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/cross-cutting-research/small-business-programs" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42111">Small Business Programs </a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/cross-cutting-research/stigma-pain-management-opioid-disorder" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/40256">Stigma in Pain Management and Opioid Use Disorder</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-2">
|
||
<a href="/research/cross-cutting-research/translating-data-action-prevent-overdose" class="menu-link gtm-topnav-third" tabindex="0" data-drupal-link-system-path="node/42121">HEAL Data2Action (HD2A)</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/research/training-next-generation-researchers" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/46831">Training the Next Generation of Researchers in HEAL</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-0">
|
||
<a href="/data" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/44206">Data</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="no-bullets menu-level-1">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/heal-data-ecosystem" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/38836">About the HEAL Data Ecosystem</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/complying-heal-data-sharing-policy" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/39216">Complying With the HEAL Data Sharing Policy</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/common-data-elements" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/39116">Common Data Elements (CDEs) Program</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/common-data-elements-repository" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/42871">Common Data Elements (CDEs) Repository</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/ecosystem-events-outreach" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/40321">HEAL Data Ecosystem Events and Outreach</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/public-access-data" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/51">HEAL Public Access and Data Sharing</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/data/data-ecosystem-collective-board" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/40951">HEAL Data Ecosystem Collective Board</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded menu-item--active-trail no-bullets nav-list-item-0">
|
||
<a href="/funding" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/221">Funding</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-1 no-bullets">
|
||
|
||
|
||
<li class="menu-item menu-item--active-trail no-bullets nav-list-item-1">
|
||
<a href="/funding/awarded" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/881">Funded Projects</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/funding/open" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/871">Open Funding Opportunities</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/funding/closed" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/876">Closed Funding Opportunities</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/funding/research-concepts" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/40206">Research Concepts</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-0">
|
||
<a href="/news" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/226">News & Events</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-1 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/news/news" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/33666">News</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/news/events" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/33671">Events</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/news/events/headliners" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/42551">Headliners Webinar Series</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/news/stories" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/33676">Research Spotlights</a>
|
||
|
||
</li>
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/videos" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/36351">Videos</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
|
||
<li class="menu-item menu-item--expanded no-bullets nav-list-item-0">
|
||
<a href="/resources" class="menu-link gtm-topnav-link" tabindex="0" data-drupal-link-system-path="node/231">Resources</a>
|
||
|
||
<button class="expand-btn" aria-label="expand-button"></button>
|
||
|
||
|
||
<ul class="menu-level-1 no-bullets">
|
||
|
||
|
||
<li class="menu-item no-bullets nav-list-item-1">
|
||
<a href="/resources/engagement" class="menu-link gtm-topnav-drop" tabindex="0" data-drupal-link-system-path="node/43166">Patient and Community Engagement</a>
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
</li>
|
||
</ul>
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
</nav>
|
||
|
||
|
||
</header>
|
||
|
||
<div data-drupal-messages-fallback class="hidden"></div><span data-big-pipe-placeholder-id="callback=Drupal%5CCore%5CRender%5CElement%5CStatusMessages%3A%3ArenderMessages&args%5B0%5D&token=_HAdUpwWmet0TOTe2PSiJuMntExoshbm1kh2wQzzzAA">
|
||
</span>
|
||
|
||
|
||
|
||
|
||
<div class="color-gradient"></div>
|
||
|
||
<main role="main">
|
||
<div class="container">
|
||
<a id="main-content" tabindex="-1"></a>
|
||
<div class="row">
|
||
<div class="col-sm-12 breadcrumb-col col-md-7">
|
||
<div id="block-particle-breadcrumbs">
|
||
|
||
|
||
|
||
|
||
<nav aria-label="breadcrumb" role="navigation">
|
||
<ol class="breadcrumb">
|
||
<li class="breadcrumb-item gtm-breadcrumb"><a href="/" class="gtm-breadcrumb">Home</a></li>
|
||
<li class="breadcrumb-item gtm-breadcrumb"><a href="/funding" class="gtm-breadcrumb">Funding</a></li>
|
||
<li class="breadcrumb-item active is-active gtm-breadcrumb" aria-current="page">Funded Projects</li>
|
||
</ol>
|
||
</nav>
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
<div class="col-sm-12 col-md-5">
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<div class="layout-content">
|
||
<div>
|
||
<div id="block-particle-content">
|
||
|
||
|
||
|
||
|
||
<h1> Funded Projects </h1>
|
||
|
||
|
||
<div>
|
||
|
||
<div class="paragraph paragraph--type--basic-content paragraph--view-mode--default">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<div class="container">
|
||
<div class='basic-content content-align-left padding-bottom--1'>
|
||
<div class='basic-content-grid-container ' style=''>
|
||
<div class="basic-content-grid-no-media">
|
||
<div>
|
||
|
||
<p>Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.</p>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
<div class="paragraph paragraph--type--dynamic-content paragraph--view-mode--default">
|
||
|
||
|
||
|
||
|
||
<div class='container'>
|
||
<div class="dynamic_content">
|
||
|
||
|
||
<div class="views-element-container form-group"><div class="funding js-view-dom-id-a91e369a34a0b0c8121651c976dbf6e8745251b4871585c9f09fe6bcabf53144">
|
||
|
||
|
||
|
||
|
||
<div class="container">
|
||
<form class="views-exposed-form" data-drupal-selector="views-exposed-form-database-block-6" action="/database/export" method="get" id="views-exposed-form-database-block-6" accept-charset="UTF-8">
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<div class="container">
|
||
<div id="filters" class="filters">
|
||
<div class='filter-row'>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-textfield form-item-institutions js-form-item-institutions form-no-label">
|
||
<input placeholder="PI or Grantee Institution" aria-label="PI or Grantee Institution" class="gtm-database-category form-text" data-drupal-selector="edit-institutions" type="text" id="edit-institutions" name="institutions" value="" size="30" maxlength="128" />
|
||
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-textfield form-item-locations js-form-item-locations form-no-label">
|
||
<input placeholder="Grantee Location" aria-label="Grantee Location" class="gtm-database-category form-text" data-drupal-selector="edit-locations" type="text" id="edit-locations" name="locations" value="" size="30" maxlength="128" />
|
||
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-textfield form-item-combine js-form-item-combine form-no-label">
|
||
<input placeholder="Enter Keywords" aria-label="Enter Keywords" class="combine-field form-text" data-drupal-selector="edit-combine" type="text" id="edit-combine" name="combine" value="" size="30" maxlength="128" />
|
||
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-submit keywords">
|
||
<input class="btn btn-alto gtm-database-search button js-form-submit form-submit" data-drupal-selector="edit-submit-database" type="submit" id="edit-submit-database" value="Search">
|
||
</div>
|
||
</div>
|
||
<div class='filter-row'>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-select form-item-rfa js-form-item-rfa form-no-label">
|
||
<select aria-label="Research Focus Area" data-drupal-selector="edit-rfa" id="edit-rfa" name="rfa" class="form-select"><option value="All" selected="selected">Research Focus Area</option><option value="81">Clinical Research in Pain Management</option><option value="40331">Cross-Cutting Research</option><option value="71">Enhanced Outcomes for Infants and Children Exposed to Opioids</option><option value="66">New Strategies to Prevent and Treat Opioid Addiction</option><option value="76">Novel Therapeutic Options for Opioid Use Disorder and Overdose</option><option value="86">Preclinical and Translational Research in Pain Management</option><option value="46831">Training the Next Generation of Researchers in HEAL</option><option value="61">Translation of Research to Practice for the Treatment of Opioid Addiction</option></select>
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-select form-item-research-program js-form-item-research-program form-no-label">
|
||
<select aria-label="Research Program" data-drupal-selector="edit-research-program" id="edit-research-program" name="research_program" class="form-select"><option value="All">Research Program</option><option value="186">Acute to Chronic Pain Signatures Program</option><option value="136">Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW)</option><option value="42106">Advancing Health Equity in Pain Management </option><option value="161">Back Pain Consortium Research Program</option><option value="106">Behavioral Research to Improve Medication-Based Treatment</option><option value="42126">Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)</option><option value="206">Development and Optimization of Non-Addictive Therapies to Treat Pain</option><option value="151">Development of Novel Immunotherapeutics for Opioid Addiction</option><option value="191">Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions</option><option value="216">Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain</option><option value="176">Early Phase Pain Investigation Clinical Network (EPPIC-Net)</option><option value="96">Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids</option><option value="146" selected="selected">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</option><option value="41416">Harm Reduction Research Network</option><option value="42121">HEAL Data2Action (HD2A)</option><option value="91">HEALing Communities Study</option><option value="141">HEALthy Brain and Child Development (HBCD) Study</option><option value="42146">Improving Delivery of Healthcare Services for Polysubstance Use</option><option value="181">Integrated Approach to Pain and Opioid Use in Hemodialysis Patients</option><option value="44116">Integrated Basic and Clinical Team-Based Research in Pain</option><option value="101">Justice Community Overdose Innovation Network (JCOIN)</option><option value="42116">Leveraging Existing and Real-Time Opioid and Pain Management Data</option><option value="42586">Native Collective Research Effort to Enhance Wellness (N CREW) Program: Addressing Overdose, Substance Use, Mental Health, and Pain </option><option value="111">Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions</option><option value="126">Optimizing the Duration, Retention, and Discontinuation of Medication Treatment for Opioid Use Disorder</option><option value="44086">Optimizing the Quality, Reach, and Impact of Addiction Services</option><option value="44106">Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders</option><option value="166">Pain Management Effectiveness Research Network (ERN)</option><option value="171">Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM)</option><option value="211">Preclinical Screening Platform for Pain</option><option value="116">Preventing Opioid Use Disorder </option><option value="44091">Prevention and Management of Chronic Pain in Rural Populations</option><option value="131">Prevention of Progression to Moderate or Severe Opioid Use Disorder</option><option value="44111">Rapidly Assessing the Public Health Impact of Emerging Opioid Threats</option><option value="39646">Recovery Research Networks</option><option value="39621">Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL)</option><option value="42136">Restoring Joint Health and Function to Reduce Pain (RE-JOIN)</option><option value="121">Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery</option><option value="42111">Small Business Programs</option><option value="40256">Stigma in Pain Management and Opioid Use Disorder</option><option value="44096">The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development</option><option value="42151">The Continuum of Care in Hospitalized Patients with Opioid Use Disorder and Infectious Complications of Drug Use (CHOICE)</option><option value="201">Translating Discoveries into Effective Devices to Treat Pain</option><option value="196">Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder</option><option value="44101">Virtual Assessments to Understand Developmental Trajectories of Substance Use Exposure</option></select>
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-select form-item-year js-form-item-year form-no-label">
|
||
<select data-drupal-selector="edit-year" id="edit-year" name="year" class="form-select"><option value="" selected="selected">Year Awarded</option><option value="2024">2024</option><option value="2023">2023</option><option value="2022">2022</option><option value="2021">2021</option><option value="2020">2020</option><option value="2019">2019</option><option value="2018">2018</option></select>
|
||
</div>
|
||
|
||
</div>
|
||
<div class="form-item-submit apply">
|
||
|
||
<div data-drupal-selector="edit-actions" class="form-actions form-group" id="edit-actions"><input class="btn btn-secondary gtm-database-filter button js-form-submit form-submit" data-drupal-selector="edit-submit-database" type="submit" id="edit-submit-database" value="Apply Filters" />
|
||
</div>
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
<a class="advanced-search reset-button btn btn-secondary" href=/funding/awarded>
|
||
Reset
|
||
</a>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="container">
|
||
<div class="results">
|
||
<div class="form-item-input">
|
||
|
||
<div class="form-group js-form-item form-item js-form-type-select form-item-items-per-page js-form-item-items-per-page form-no-label">
|
||
<label for="edit-items-per-page" class="visually-hidden">Show</label>
|
||
<select aria-label="How many items per page" data-drupal-selector="edit-items-per-page" id="edit-items-per-page" name="items_per_page" class="form-select"><option value="2">Show 2 per page</option><option value="5">Show 5 per page</option><option value="10">Show 10 per page</option><option value="25" selected="selected">Show 25 per page</option><option value="50">Show 50 per page</option></select>
|
||
</div>
|
||
|
||
</div>
|
||
<div>
|
||
<a class="file-export" href="/funding/awarded/export?research_program=146&_format=csv">Download Results</a>
|
||
<a href="#" class="gtm-copy-query copybutton" aria-label="Copy the URL for your results" data-copy="https://heal.nih.gov/funding/awarded?research_program=146">Save this Search</a>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</form>
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<div class="container-fluid">
|
||
<table class="cols-10 table-striped table-bordered table">
|
||
<thead class="thead-dark">
|
||
<tr>
|
||
<th id="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_reporter_number&sort=asc" title="sort by Project #">Project #</a></th>
|
||
<th id="view-title-table-column" class="views-field views-field-title" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=title&sort=asc" title="sort by Project Title">Project Title</a></th>
|
||
<th id="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area" scope="col">Research Focus Area</th>
|
||
<th id="view-field-research-program-table-column" class="views-field views-field-field-research-program" scope="col">Research Program</th>
|
||
<th id="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_administering_ics&sort=asc" title="sort by Administering IC">Administering IC</a></th>
|
||
<th id="view-field-institutions-table-column" class="views-field views-field-field-institutions" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_institutions&sort=asc" title="sort by Institution(s)">Institution(s)</a></th>
|
||
<th id="view-field-investigators-table-column" class="views-field views-field-field-investigators" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_investigators&sort=asc" title="sort by Investigator(s)">Investigator(s)</a></th>
|
||
<th id="view-field-locations-table-column" class="views-field views-field-field-locations" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_locations&sort=asc" title="sort by Location(s)">Location(s)</a></th>
|
||
<th id="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded" scope="col"><a href="?page=4&research_program=146&rfa=All&institutions1=&locations1=&goal=All&combine=&grant=All&locations=&institutions=&select_location=All&year=&items_per_page=25&order=field_year_awarded&sort=asc" title="sort by Year Awarded">Year Awarded</a></th>
|
||
</tr>
|
||
</thead>
|
||
<!--
|
||
<colgroup>
|
||
<col span="1" style="width: 9%;">
|
||
<col span="1" style="width: 12%;">
|
||
<col span="1" style="width: 15%;">
|
||
<col span="1" style="width: 15%;">
|
||
<col span="1" style="width: 9%;">
|
||
<col span="1" style="width: 9%;">
|
||
<col span="1" style="width: 9%;">
|
||
<col span="1" style="width: 9%;">
|
||
<col span="1" style="width: 9%;">
|
||
</colgroup>
|
||
-->
|
||
<tbody>
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34551"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9745741&amp;icde=46462754" target="_blank">1R03DA046011-01A1</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary1" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Opioid sparing potential of light-induced analgesia: a pilot trial of a novel, non-pharmacological treatment for pain </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">DUKE UNIVERSITY </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Gulur, Padma </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Durham, NC </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary1" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> NIDA Small Research Grant Program (R03 Clinical Trial Required)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-634.html" target="_blank">PA-18-634</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Exposure to opioid analgesics during medical care is a key driver of the opioid epidemic. Such exposures are widespread. Yet opioids remain essential first-line agents in treating pain, and it remains vital that pain be appropriately managed. Non-opioid pain treatments help to resolve the opioid/pain conflict. This project will examine the opioid-sparing and pain-relieving potential of a novel, non-pharmacological treatment for pain, using the effects of green light exposure to reduce pain and thereby reduce the quantity of opioids needed for pain relief.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34801"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9737592&amp;icde=46731192" target="_blank">1UG3DA048385-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary2" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Development of novel therapeutics for opioid dependence </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">KENNY, PAUL J.; KAMENECKA, THEODORE M </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">New York, NY </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2018 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary2" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>This project proposes to develop novel Gpr151 antagonists to facilitate long-term abstinence in opioid-dependent individuals. Gpr151 is an orphan G-protein coupled receptor that is expressed almost exclusively in the medial habenula and co-localizes with ?-opioid receptors to regulate the inhibitory effects of opioids on habenular neurons. Mice with a null mutation in Gpr151 (Gpr151-/- mice) are resistant to the stimulant and rewarding effects of opioids and self-administer lower quantities of oxycodone. Based on this preliminary work, the study will seek to identify Gpr151 antagonists through a variety of methods and optimize them for potency, selectivity, drug metabolism, pharmacokinetics, and brain penetration properties. The study will evaluate effects of those with the most favorable drug-like physiochemical properties on electrophysiological responses of medial habenula to opioid drugs and assess the in vivo efficacy of these novel antagonists in wild-type and Gpr151-/- mice.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35006"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9660796&amp;icde=46454074" target="_blank">1R21DA047662-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary3" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Human laboratory model to screen drugs with opioid analgesic-sparing effects: cannabidiol/morphine combinations </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">WAYNE STATE UNIVERSITY </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Lundahl, Leslie H </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Detroit, MI </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary3" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-344.html" target="_blank">PA-18-344</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Chronic pain is a significant public health problem associated with tremendous personal and economic burden. First-line treatment consists of opioid medications, but despite only moderate efficacy and unpleasant side effects, rates of opioid prescriptions have quadrupled over the past 15 years, and this has contributed to high rates of misuse, overdose, and mortality. Clearly, alternative, or non-opioid strategies for treating pain are needed. In this context, “opioid-sparing” medications refer to compounds that can be combined with and enhance the analgesic effects of lower-dose opioids without increasing the rewarding properties of either drug. There is preclinical evidence suggesting that cannabidiol (CBD) may have the potential to function as “opioid-sparing” medications, but its ability to alter opioid-mediated analgesia in humans has yet to be determined. This proposal will fill this gap by conducting a double-blind, placebo-controlled, within-subject randomized crossover study of the effects of CBD and morphine co-administration on pain sensitivity and subjective reinforcement on 28 healthy males and females. This is the first known study to investigate the ability of CBD to alter morphine’s analgesic effects in humans. If successful, the model will have a lasting impact on our ability to develop and test medications that reduce our reliance on chronic use of opioid medications for pain relief.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35206"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9677597&amp;icde=46452481" target="_blank">1UG3DA047717-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary4" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">MOR/DOR Heterodimer Antagonists: A Novel Treatment for Opioid Dependence </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">WASHINGTON STATE UNIVERSITY </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">MORGAN, MICHAEL M </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Pullman, WA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary4" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Tens of thousands of people die each year from opioid overdose. Many of these people began taking opioids for pain. A critical treatment goal is to reduce the development of opioid dependence either by enhancing opioid analgesia so lower doses can be used or by blocking withdrawal symptoms. Current pharmacological treatments in these two categories, although effective, present serious limitations. The recent finding that reducing the signaling through mu-delta opioid heterodimers appears to enhance opioid antinociception and reduce dependence suggests that a blocker of mixed mu-delta receptors (MDOR antagonist) could be effective in reducing dependence by limiting opioid tolerance and preventing opioid withdrawal. This research group has developed a compound with that characteristic, called D24M, which preliminary studies have shown could reduce opioid dependence by enhancing opioid antinociception, reducing opioid tolerance, or directly inhibiting opioid withdrawal. They propose to extend this research by investigating whether it can reduce chronic pain in an animal model that mimics the clinical situation of pain patients who transition to dependence. If these studies are successful, they could lead to the development of an optimized drug ready for Investigational New Drug (IND) application and enable translational and clinical testing.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35541"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9843968" target="_blank">1UG3DA049598-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary5" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">Epiodyne, Inc. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Schmidt, William </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">San Francisco, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary5" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Opioid use disorder (OUD) and opioid overdose (OD) are major health issues. Breathing can be restored after OD by naloxone, but its short half-life can require multiple administrations to reverse OD, and OD symptoms may return after initial reversal if illicit opioids are still present after the effects of naloxone have worn off. Additionally, while the standard treatment of OUD with buprenorphine and methadone reduces relapse and mortality, access and adoption are limited by dosage forms, metabolic liabilities, and potential for misuse and diversion. This study seeks to develop chemically novel, potent mu-opioid receptor (MOR) antagonists and low- and mid-efficacy partial agonists. Current lead counts can outcompete opioid overdoses in preclinical models with a longer half-life, a key naloxone liability for treating OD. The potent, low-efficacy partial agonists add a low opioid tone, diminishing the aversive effects of pure antagonists. These, and the mid-efficacy partial agonists, are leads to maintenance therapeutics for OUD.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-36046"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9891326" target="_blank">1UG3DA048387-01A1</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary6" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Methocinnamox (MCAM): A novel ?-opioid receptor antagonist for opioid use disorders </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">University of Texas Health Science Center San Antonio </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Woods, James </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">San Antonio, TX </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary6" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>MCAM is a novel opioid antagonist that can be used for opioid overdose reversal and has advantages over naloxone, including a pseudo-irreversible interaction with the ?-opioid receptor and a longer duration of action. Studies in animal models demonstrate MCAM’s long duration of action against the reinforcing and respiratory-depressant effects of remifentanil and heroin, indicating that could be a better treatment option for opioid use disorder. This project studies the pharmacodynamics of MCAM through animal toxicity and safety studies to establish the necessary and sufficient conditions from which to establish MCAM’s safety and antagonist activity in animals and humans. MCAM may be able to prevent all actions of any ?-receptor opioid drug in humans for a longer period of time than any other antagonist given acutely.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-33851"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9904278" target="_blank">1UG3DA050310-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary7" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">A once-weekly oral methadone for maintenance therapy for opioid use disorder </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">Lyndra Therapeutics, Inc. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Bellinger, Andrew; Zale, Steve </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Boston, MA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary7" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Methadone maintenance therapy has been shown to facilitate recovery and prevent deaths from opioid use disorder (OUD). This proposal is for development of a once-weekly oral methadone for maintenance therapy for OUD. Lyndra has developed an oral gastric residence dosage form that has been demonstrated to provide at least seven days of continuous delivery. A once-weekly oral methadone product could lower a major barrier to treatment for many patients, reduce the stigma and socioeconomic impact of medication-assisted therapy, and increase the capacity of methadone treatment centers by reducing the number of patient visits. This study will perform pharmaceutical development and pharmacological characterization of a once-weekly oral methadone dosage form, leading to the selection of a clinical candidate for a first-in-human trial and submission of an IND. Clinical trials will then be performed to evaluate the safety and pharmacokinetics of the once-weekly oral methadone dosage form in subjects with OUD.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34281"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9905187" target="_blank">1UG3DA050322-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary8" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">Yale University </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">DiLeone, Ralph </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">New Haven, CT </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary8" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>This study will conduct preclinical and clinical assessments of the NMDA modulator NYX-783 for treatment of opioid drug-seeking and relapse to opioid use disorder (OUD). NYX-783, a novel small molecule being developed by Aptinyx, has shown evidence of safety/tolerability in Phase 1 studies and is currently in Phase 2 trials for post-traumatic stress disorder. This project will test the safety, tolerability, and pharmacokinetics (PK) of NYX-718 in morphine-maintained patients in residential settings and then conduct a combined inpatient (safety/tolerability/PK) / outpatient (preliminary efficacy) study testing NYX-783’s effects on opioid use and relapse, stress/cue reactivity, craving, and quality of life in OUD subjects maintained on standard extended release naltrexone over a 10-week period. Successful completion of these studies will set the stage for larger scale Phase 2/3 studies of efficacy in OUD that will ultimately be required for FDA approval of NYX-783 for the treatment of drug-seeking and relapse in OUD.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34666"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9790420&amp;icde=46453373" target="_blank">1UG3DA048734-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary9" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">JOHNS HOPKINS UNIVERSITY </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">HUHN, ANDREW S; DUNN, KELLY E. </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Baltimore, MD </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary9" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>A recent FDA public meeting identified sleep disturbance as a primary contributor to opioid use disorder (OUD) treatment failure. Suvorexant (SUVO; Belsomra®) is a dual orexin receptor antagonist that is FDA-approved for insomnia, with low addiction liability, that improves sleep continuity with a single dose, has an extremely safe and mild side-effect profile, has clear interactions with the opioid system, and has not yet been evaluated in OUD patients. The hypothesis is that SUVO will improve total sleep time during withdrawal, have no addiction liability, and be more efficacious than trazodone, a common OUD-associated insomnia medication. Primary outcomes will be objective sleep measures and addiction liability. Secondary measures will include objective, biological, and self-report measures of opioid withdrawal severity, treatment retention, craving, and stress. Results will advance the treatment of OUD, the understanding of sleep and opioids, and the use of SUVO in clinical populations.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34851"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9778797&amp;icde=46463228" target="_blank">5UG3DA047682-02</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary10" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">ENSYSCE BIOSCIENCES, INC. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Kirkpatrick,Lynn </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">San Diego, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary10" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html">DA19-002</a>
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35051"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9736358&amp;icde=46453085" target="_blank">1UG3DA048375-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary11" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">ADYNXX, INC. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">MAMET, JULIEN; MANNING, DONALD C </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">San Francisco, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary11" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>There is an urgent need to prevent and reduce opioid use disorder (OUD) by reducing the need for opioid analgesia and preventing the escalation of opioid dosing in patients at greater risk of using more opioids following surgery. Brivoligide is a non-opioid drug candidate that can alter the course of postoperative pain for patients most likely to suffer increased pain and utilize more opioids following surgery. A single administration of brivoligide at the time of surgery can reduce acute postoperative pain in these patients by 30 percent to 40 percent beyond what can be achieved with the current standard of care for at least 28 days and reduce opioid utilization by 40 percent over a 3-month period following surgery. This project will support the research necessary to achieve regulatory approval of brivoligide with a broad indication, which will initially focus on the reduction of postoperative pain following mastectomy, a soft-tissue surgery model suitable to detect long-term pain and opioid reduction benefits. Brivoligide appears to be a very promising pharmacotherapy with the potential to greatly contribute to stemming the tide in the opioid crisis.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35286"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9653772&amp;icde=46453835" target="_blank">1R01DA047574-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary12" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">In vivo characterization of opioid biased agonists </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">MCLEAN HOSPITAL </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Paronis, Carol A; Bergman, Jack </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Belmont, MA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary12" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Prescription Drug Abuse (R01 Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-058.html" target="_blank">PA-18-058</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>The ongoing opioid crisis has led to renewed concerns about the clinical prescription of addictive opioid analgesics. However, there are currently no suitable alternatives for treating severe or malignant pain. Studies of opioid signaling mechanisms in mice deficient in ?-arrestin have suggested that biased agonists displaying preferential activation of G-protein signaling over ?-arrestin signaling could offer a promising avenue for the development of opioid analgesics with a reduced adverse effects profile. However, there is no concluding evidence showing that such biased signaling can indeed be associated with reduced opioid side effects and, consequently, an improved safety profile. This research will address the need for preclinical data to rigorously evaluate this hypothesis with a program of in vivo studies to compare the effects of “balanced” opioids (morphine, oxycodone, and fentanyl) with that of the “biased” agonists PZM21 and two novel ligands provided by colleagues at the NIDA IRP in nonhuman primates. The results of these studies will provide critical information regarding the dependence liability of “biased” agonists that, in clinical practice, might be given on a repeated, or chronic, basis, potentially adding a powerful new tool for the safer management of severe or malignant pain.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35721"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9661530&amp;icde=46462093" target="_blank">1R01DA045695-01A1</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary13" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">BOSTON UNIVERSITY MEDICAL CAMPUS </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Stein, Michael D; Weisberg, Risa B </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Boston, MA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary13" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-055.html" target="_blank">PA-18-055</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Often (around 40 percent of the time), individuals being treated for opioid use disorder (OUD) also have pain that interferes with daily life. This study builds on the prior development of a collaborative primary care approach, entitled TOPPS (Treating Opioid Patients’ Pain and Sadness), in which behavioral health specialists and primary care providers share a unified plan for addressing pain and depression in patients receiving buprenorphine. Building in preliminary work, researchers are conducting a randomized controlled trial of TOPPS compared to a health education contact-control condition among 250 persons with OUD recruited from two primary care-based buprenorphine programs, provided over 3 months and followed over 12 months. The study will examine whether this intervention changes how much pain interferes with daily functioning, the severity of pain, depression, and whether individuals stay in OUD treatment.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-36111"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9796252&amp;icde=46453373" target="_blank">1UG3DA048775-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary14" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Novel nanovaccines against opioid use disorders </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">VIRGINIA POLYTECHNIC INST AND ST UNIV </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">ZHANG, CHENMING M; PRAVETONI, MARCO </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Blacksburg, VA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary14" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Opioid use disorders (OUD) are a national public health emergency with more than 115 fatal overdoses occurring each day in the U.S. and an economic burden of more than $78 billion a year. Several medications are available for treating OUD, but their access is limited and efficacy is often sub-optimal. It is thus urgent to develop new, affordable strategies for the effective treatment of OUD. Immunopharmacotherapy has emerged as a promising treatment approach against OUD that relies on the induction of drug-specific antibodies to neutralize circulating drug molecules and reduce or cancel their effects. Several groups have attempted to apply this strategy with mixed results, suggesting that novel immunization platforms must be tested to further improve vaccine efficacy against OUD. This project will fabricate novel nanoparticle-based vaccines against OUD that are likely to boost their immunogenicity and lead to a more robust and effective immune response against the target opioid. The broad impact of this project resides in the rational design of nanoparticle-based vaccines that are safe and effective against opioids. This novel nanoparticle-based immunization strategy can be applied to the development of next-generation vaccines against a range of OUD and other substance use disorders.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-33966"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9697952&amp;icde=46452708" target="_blank">1UG3DA047925-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary15" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder. </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">BIOCORRX, INC. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">BRAR, BALBIR </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Anaheim, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary15" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>The opioid antagonist naltrexone (NTX) is a proven treatment for opioid use disorder (OUD); however, lack of adherence is a serious limitation that has prevented NTX from reaching its maximum therapeutic potential. To address this limitation, BioCorRx is developing BICX102, a subcutaneous solid depot pellet of NTX, a single implantation of which can provide continual blockade of opioid receptors for up to 3 months. This can prevent patients from being adversely affected by almost any opioid relapse event, while improving efficacy and adherence to behavioral programs that support long-term management and recovery. This proposal comprises the steps required to achieve FDA approval. Successful development of BICX102 would result in a safe and effective 3-month subcutaneous depot pellet/implant containing NTX (1,000 mg) that would be far less reliant on patient compliance.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34531"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9905170" target="_blank">1UG3DA050325-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary16" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">Pennsylvania State University Hershey Medical Center </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Grigson, Patricia </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Hershey, PA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary16" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>High relapse rates among people with opioid use disorder (OUD) indicate that addiction involves appetitive pathways. Peripheral stimulation of the glucagon-like peptide-1 receptor (GLP-1R) “satiety” pathway could reduce heroin seeking and taking. Pretreatment with a GLP-1R agonist reduces heroin taking, seeking, and drug-induced reinstatement in rats. This project tests whether GLP-1R agonists can reduce relapse in humans with OUD. A pilot study will be conducted to determine whether once-daily treatment with the shorter acting GLP-1R agonist, liraglutide, can safely and effectively reduce cravings among OUD patients. Animal models will be used to test the efficacy and safety of a longer-acting GLP-1R agonist, semaglutide, and then a clinical trial will be conducted to test whether semaglutide will reduce relapse and use in animal models. If successful, the study will show that treatment with GLP-1R agonists can safely and effectively reduce opioid craving, seeking, and relapse.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34761"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9852022" target="_blank">1UG3DA049694-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary17" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone? </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">University of Pennsylvania </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Kampman, Kyle </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Philadelphia, PA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary17" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Extended-release naltrexone (XR-NTX) reduces overdose risk; however, transitioning to XR-NTX requires detoxification, which is a major hurdle. Non-opioid detoxification with an alpha-2 adrenergic receptor agonist, such as lofexidine, may shorten detoxification time, but it does not reduce the subjective effects of withdrawal. Pregabalin potentiates the activity of glutamic acid decarboxylase, inhibits calcium influx and release of excitatory neurotransmitters, raises GABA levels, and is approved for neuropathic pain, for fibromyalgia, and as an adjunctive therapy for adults with partial onset seizures. The study will test whether pregabalin can be combined with lofexidine to better reduce the subjective effects of opioid withdrawal than lofexidine alone and increase the proportion of patients that transition to XR-NTX. Such a dosing combination could lower the detoxification hurdle for patients who are interested in antagonist treatment or who are in settings where it is unavailable or difficult to access.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34896"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9676930&amp;icde=46451906" target="_blank">1UG3DA047708-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary18" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Development of a safe and effective novel mechanism analgesic to treat moderate to severe pain with low or absent abuse liability. </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">ARTYS BIOTECH, LLC </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">LARK, MICHAEL WILLIAM; ZADINA, JAMES E </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Plymouth Meeting, PA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary18" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Chronic pain affects an estimated 100 million Americans, or one third of the U.S. population, and it is the primary reason Americans are on disability. Although many treatments are available for pain, the most potent class of analgesics relies on opioid analogs, whose limitations and well-known adverse effects have contributed to the present opioid crisis. New pharmacotherapies for pain management are sorely needed. MTX1604, a synthetic endomorphin analog, has emerged as a highly effective analgesic that exhibits reduced reward potential and respiratory suppression, and a robust duration of efficacy in a variety of validated animal models of acute, neuropathic, inflammatory, post-operative, and visceral pain. This project will generate additional preclinical characterization data of MTX1604 and advance clinical development toward FDA approval. If successful, this medication development project could offer patients a novel non-addictive, potent, and safe analgesic and thus have a direct impact on the opioid crisis.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35126"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9829460&amp;icde=46453701" target="_blank">3UG3DA048351-01S1</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary19" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge. </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">HENRY M. JACKSON FDN FOR THE ADV MIL/MED </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">MATYAS, GARY R </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Bethesda, MD </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary19" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html">RFA-DA-19-002</a>
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35386"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9788385&amp;icde=46463154" target="_blank">5UG3DA047714-02</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary20" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">WEST VIRGINIA UNIVERSITY </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Rezai, Ali R </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Morgantown, WV </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary20" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-18-494.html">PAR-18-494</a>
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-35806"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9674194&amp;icde=46453916" target="_blank">1U01DA047713-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary21" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">PTPRD ligands for stimulant and opiate use disorders </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Uhl, George Richard </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Albuquerque, NM </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary21" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-18-219.html" target="_blank">PAR-18-219</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>There are no FDA-approved medications for stimulant use disorders, and therapies for opioid use disorders remain suboptimal in ways that are now a focus of national attention. Thus, there is a clear need to identify new targets and explore new approaches for addiction medication development. Several lines of evidence suggest that PTPRD (receptor type protein tyrosine phosphatase D) may be a promising target for development of pharmacotherapeutics to treat not only stimulant use disorders but opioid use disorders as well. This research will focus on improving existing PTPRD ligands, identifying their effects on the dopamine and opioid systems, and moving the best novel, patentable PTPRD ligands toward human studies. If successful, this project will generate novel, well-tolerated, and bioavailable PTPRD ligands that display in vitro potency, selectivity and stability, and in vivo modulation of both cocaine and opioid-mediated reward at doses that present no significant toxicity.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-33841"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9778798&amp;icde=46451906" target="_blank">1UG3DA047707-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary22" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">TITAN PHARMACEUTICALS, INC. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">BEEBE DEVARNEY, KATHERINE L </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">South San Francisco, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary22" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>There is a need for an opioid use disorder (OUD) treatment that can prevent relapse in detoxified subjects. Titan's proprietary subdermal implants can provide long-term, non-fluctuating therapeutic levels of drug continuously following a single office-based insertion procedure. The non-biodegradable solid matrix implant formulation virtually eliminates the risk of accidental drug dumping and associated serious toxicity, and its subdermal location assures patient compliance for the 6-month treatment duration. Nalmefene hydrochloride (nalmefene) is an opioid receptor antagonist approved for the management and reversal of opioid overdose. Prototype nalmefene implants inserted subdermally in rats delivered nalmefene continuously for months without any observable safety concerns. This proposed study will develop a 6-month implantable device that delivers nalmefene at a steady rate to prevent relapse to opioid dependence following opioid detoxification. This project will manufacture nalmefene implants, complete nonclinical safety and pharmacology studies, and conduct clinical studies in OUD subjects to support a New Drug Application.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34151"> <a href="https://projectreporter.nih.gov/project_info_details.cfm?aid=9778811&amp;icde=46451247" target="_blank">1UG3DA047711-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary23" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">NEW YORK STATE PSYCHIATRIC INSTITUTE </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">COMER, SANDRA D; PRAVETONI, MARCO </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">New York, NY </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary23" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>The current studies are designed to examine a novel approach to treating OUD, namely use of a vaccine (OXY-KLH) targeted against oxycodone, one of the most commonly misused prescription opioids, and a vaccine (M-KLH) targeted against heroin/morphine. The researchers will evaluate the safety, immunogenicity, and preliminary efficacy of OXY-KLH and M-KLH. Overall, the proposed studies will provide a great deal of information about the safety and potential efficacy of the vaccines in reducing the addiction liability of opioids, which will be administered in a controlled laboratory setting. If the outcomes of the proposed studies with OXY-KLH and M-KLH are favorable, development of the bivalent vaccine (OXY-KLH plus M-KLH) that will target oxycodone and heroin will proceed. The long-term goal of this research is to develop a multivalent vaccine directed against oxycodone, heroin, and other relevant opioids.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="even">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34571"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9796632" target="_blank">1UG3DA048767-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary24" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">Eicosis, LLC </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">Hammock, Bruce </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">Davis, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary24" class="summary collapse even fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>EicOsis is developing a first-in-class analgesic with efficacy against neuropathic pain that will reduce or replace the need for opioids and thus potentially prevent opioid use disorder (OUD). The target of the small molecule inhibitor EC5026 is the soluble epoxide hydrolase, a master regulatory enzyme that modulates the activity of endogenous bioactive lipids. The study will reach the next steps in clinical human clinical trials with EC5026 through additional preclinical studies to expand the efficacy into models of chronic pain conditions. Additionally, detailed pharmacokinetic, metabolism, and distribution studies are proposed that will provide the required information to optimize drug formulation and for advanced clinical trials examining efficacy in humans. EicOsis is meeting current development goals, and EC5026 is well positioned to meet the urgent need of reducing opioid use.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
<tr class="odd">
|
||
|
||
<td headers="view-field-reporter-number-table-column" class="views-field views-field-field-reporter-number">
|
||
<span id="project-title-34841"> <a href="https://projectreporter.nih.gov/project_info_description.cfm?aid=9778797&amp;icde=46450216&amp;ddparam=&amp;ddvalue=&amp;ddsub=&amp;cr=11&amp;csb=default&amp;cs=ASC&amp;pball=" target="_blank">1UG3DA047682-01</a>
|
||
</span>
|
||
<br>
|
||
<a class="expand-link" data-toggle="collapse" href="#summary25" role="button" aria-expanded="false" aria-controls="collapseExample">
|
||
Show Summary
|
||
</a>
|
||
</td>
|
||
|
||
<td headers="view-title-table-column" class="views-field views-field-title">PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial </td>
|
||
|
||
<td headers="view-field-research-focus-area-table-column" class="views-field views-field-field-research-focus-area"><a href="/research/therapeutic-options" hreflang="en">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-research-program-table-column" class="views-field views-field-field-research-program"><a href="/research/therapeutic-options/focusing-development" hreflang="en">Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose</a> </td>
|
||
|
||
<td headers="view-field-administering-ics-table-column" class="views-field views-field-field-administering-ics">NIDA </td>
|
||
|
||
<td headers="view-field-institutions-table-column" class="views-field views-field-field-institutions">ENSYSCE BIOSCIENCES, INC. </td>
|
||
|
||
<td headers="view-field-investigators-table-column" class="views-field views-field-field-investigators">KIRKPATRICK, LYNN </td>
|
||
|
||
<td headers="view-field-locations-table-column" class="views-field views-field-field-locations">San Diego, CA </td>
|
||
|
||
<td headers="view-field-year-awarded-table-column" class="views-field views-field-field-year-awarded">2019 </td>
|
||
|
||
</tr> <!-- closing head of time -->
|
||
|
||
<tr id="summary25" class="summary collapse odd fullSummary">
|
||
<td colspan="9">
|
||
<div class="offset-xl-1 offset-lg-1 offset-md-1 col-10 db-summary">
|
||
<strong>NOFO Title:</strong> Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
|
||
<br>
|
||
<strong>NOFO Number:</strong> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-002.html" target="_blank">RFA-DA-19-002</a>
|
||
<br>
|
||
<strong>Summary:</strong>
|
||
<br>
|
||
<p>Several abuse-deterrent opioid products (primarily formulations) are currently marketed or in clinical development, but they fall short of being resistant to abuse. Rather than abuse-deterrent formulations, this project, in partnership with Ensyce Biosciences, has created two complementary, novel technologies that control the release of known opioids. One technology delivers prodrugs — drugs that are not active until they have been exposed to the right conditions within the body, at which point they are gradually converted into active drugs, making them difficult to tamper with and reducing the potential for misuse. Another technology makes it so that taking increasing numbers of pills inhibits the process of converting prodrug into active drug, reducing the potential for overdose. This project aims to refine the development of these two technologies and work to combine them, and to translate promising animal results into human use.</p>
|
||
|
||
|
||
</div>
|
||
</td>
|
||
</tr> <!-- summary-->
|
||
|
||
|
||
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
|
||
|
||
<nav class="pager" role="navigation" aria-label="Paginaton navigation">
|
||
<ul class="pagination pager__items js-pager__items flex-wrap">
|
||
<li class="page-item pager__item pager__item--first">
|
||
<a href="?research_program=146&page=0" title="Go to first page" class="page-link">
|
||
<span class="visually-hidden">First page</span>
|
||
<span aria-hidden="true">« First</span>
|
||
</a>
|
||
</li>
|
||
<li class="page-item pager__item pager__item--previous">
|
||
<a href="?research_program=146&page=3" title="Go to previous page" rel="prev" class="page-link">
|
||
<span class="visually-hidden">Previous page</span>
|
||
<span aria-hidden="true">‹‹</span>
|
||
</a>
|
||
</li>
|
||
<li class="page-item pager__item">
|
||
<a href="?research_program=146&page=0" title="Go to page 1" class="page-link">
|
||
<span class="visually-hidden">
|
||
Page
|
||
</span>1</a>
|
||
</li>
|
||
<li class="page-item pager__item">
|
||
<a href="?research_program=146&page=1" title="Go to page 2" class="page-link">
|
||
<span class="visually-hidden">
|
||
Page
|
||
</span>2</a>
|
||
</li>
|
||
<li class="page-item pager__item">
|
||
<a href="?research_program=146&page=2" title="Go to page 3" class="page-link">
|
||
<span class="visually-hidden">
|
||
Page
|
||
</span>3</a>
|
||
</li>
|
||
<li class="page-item pager__item">
|
||
<a href="?research_program=146&page=3" title="Go to page 4" class="page-link">
|
||
<span class="visually-hidden">
|
||
Page
|
||
</span>4</a>
|
||
</li>
|
||
<li class="page-item pager__item active">
|
||
<a href="?research_program=146&page=4" title="Current page" aria-current="page" class="page-link">
|
||
<span class="visually-hidden">
|
||
Current page
|
||
</span>5</a>
|
||
</li>
|
||
<li class="page-item pager__item">
|
||
<a href="?research_program=146&page=5" title="Go to page 6" class="page-link">
|
||
<span class="visually-hidden">
|
||
Page
|
||
</span>6</a>
|
||
</li>
|
||
<li class="page-item pager__item pager__item--next">
|
||
<a href="?research_program=146&page=5" title="Go to next page" rel="next" class="page-link">
|
||
<span class="visually-hidden">Next page</span>
|
||
<span aria-hidden="true">››</span>
|
||
</a>
|
||
</li>
|
||
<li class="page-item pager__item pager__item--last">
|
||
<a href="?research_program=146&page=5" title="Go to last page" class="page-link">
|
||
<span class="visually-hidden">Last page</span>
|
||
<span aria-hidden="true">Last »</span>
|
||
</a>
|
||
</li>
|
||
</ul>
|
||
</nav>
|
||
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
</div>
|
||
|
||
|
||
</main>
|
||
<div class="container">
|
||
<p class="last-updated">Page last updated
|
||
September 21, 2023</p>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
</div>
|
||
|
||
|
||
<footer class="fluid-container p-3 footer" role="contentinfo">
|
||
<div class="container">
|
||
<div class="row">
|
||
<div class="col-12 col-md-3">
|
||
<div class="footer-logo"><a href="/"><img alt="NIH HEAL Initiative" src="/assets/HEAL_Initaitive_White.svg" /></a></div>
|
||
|
||
<h2>Contact Us</h2>
|
||
|
||
<p>Please send email to <a href="/cdn-cgi/l/email-protection#e0a8a5a1ac9195859394898f8ea08f84ce8e8988ce878f96"><span class="__cf_email__" data-cfemail="59111c1815282c3c2a2d30363719363d77373031773e362f">[email protected]</span></a></p>
|
||
</div>
|
||
|
||
<div class="col-6 col-md-3">
|
||
<h2><a class="gtm-footer-link" href="/about">About</a></h2>
|
||
|
||
<ul class="list-unstyled">
|
||
<li><a class="gtm-footer-link" href="/about/research-plan">Research Plan</a></li>
|
||
<li><a class="gtm-footer-link" href="/about/nih-heal-initiative-leadership">Leadership</a></li>
|
||
</ul>
|
||
|
||
<h2><a class="gtm-footer-link" href="/funding">Funding</a></h2>
|
||
|
||
<ul class="list-unstyled">
|
||
<li><a class="gtm-footer-link" href="/funding/awarded">Funded Projects</a></li>
|
||
<li><a class="gtm-footer-link" href="/funding/open">Open Opportunities</a></li>
|
||
<li><a class="gtm-footer-link" href="/funding/closed">Closed Opportunities</a></li>
|
||
</ul>
|
||
|
||
<h2><a class="gtm-footer-link" href="/data">Data</a></h2>
|
||
|
||
<h2><a class="gtm-footer-link" href="/news">News</a></h2>
|
||
|
||
<h2><a class="gtm-footer-link" href="/resources">Resources</a></h2>
|
||
</div>
|
||
|
||
<div class="col-6 col-md-3">
|
||
<h2><a class="gtm-footer-link" href="/research">Research</a></h2>
|
||
|
||
<ul class="list-unstyled research-list">
|
||
<li><a class="gtm-footer-link" href="/research/research-to-practice">Translation of Research to Practice for the Treatment of Opioid Addiction</a></li>
|
||
<li><a class="gtm-footer-link" href="/research/new-strategies">New Strategies to Prevent and Treat Opioid Addiction</a></li>
|
||
<li><a class="gtm-footer-link" href="/research/infants-and-children">Enhanced Outcomes for Infants and Children Exposed to Opioids</a></li>
|
||
<li><a class="gtm-footer-link" href="/research/medication-options">Novel Therapeutic Options for Opioid Use Disorder and Overdose</a></li>
|
||
<li><a class="gtm-footer-link" href="/research/clinical-research">Clinical Research in Pain Management</a></li>
|
||
<li><a class="gtm-footer-link" href="/research/preclinical-translational">Preclinical and Translational Research in Pain Management</a></li>
|
||
<li><a href="/research/cross-cutting-research">Cross-Cutting Research</a></li>
|
||
<li><a href="/research/training-next-generation-researchers">Training the Next Generation of Researchers in HEAL</a></li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="col-12 col-md-3">
|
||
<h2>Stay Connected</h2>
|
||
|
||
<p><a href="https://public.govdelivery.com/accounts/USNIHNIDA/signup/43013" target="_blank" class="signup">Sign up for news and updates.</a></p>
|
||
|
||
<div class="footer-social-media">
|
||
<h2>Follow NIH</h2>
|
||
<a aria-label="Follow us on X" class="gtm-social-twitter" href="https://twitter.com/nih" target="_blank">
|
||
<span aria-label="Twitter Icon" class="x-icon"> </span>
|
||
</a>
|
||
<a aria-label="Follow us on Instagram" class="gtm-social-instagram" href="https://www.instagram.com/nihgov" target="_blank">
|
||
<span aria-label="Instagram Icon" class="ig-icon"> </span>
|
||
</a>
|
||
<a aria-label="Follow us on Facebook" class="gtm-social-facebook" href="https://www.facebook.com/nih.gov/" target="_blank">
|
||
<span aria-label="Facebook Icon" class="fb-icon"> </span>
|
||
</a>
|
||
<a aria-label="Visit the HEAL YouTube" class="gtm-social-youtube" href="https://www.youtube.com/playlist?list=PLd_5BzGlfpgpkK12ToGD9VtxF8ClhEusZ" target="_blank">
|
||
<span aria-label="YouTube Icon" class="yt-icon"> </span>
|
||
</a>
|
||
</div>
|
||
</div>
|
||
|
||
<hr class="col-12" />
|
||
<div class="col-md-12 gov-links">
|
||
<ul class="list-inline">
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://www.nih.gov/">NIH Home</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://salud.nih.gov/">En Español</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://www.nih.gov/web-policies-notices">Web Policies and Notices</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">HHS Vulnerability Disclosure</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office">Freedom of Information Act</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://www.edi.nih.gov/no-fear-act">No Fear Act</a></li>
|
||
<li class="list-inline-item"><a class="gtm-footer-link" href="https://oig.hhs.gov/">Office of Inspector General</a></li>
|
||
</ul>
|
||
|
||
<p><a class="gtm-footer-link" href="https://www.hhs.gov/">U.S. Department of Health and Human Services</a></p>
|
||
</div>
|
||
|
||
<div class="col-md-9 mx-auto gov-links">
|
||
<p>Helping to End Addiction Long-term<sup>®</sup> and NIH HEAL Initiative<sup>®</sup> are registered service marks of the Department of Health and Human Services.</p>
|
||
</div>
|
||
</div>
|
||
</footer>
|
||
|
||
|
||
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/881","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"page":"4","research_program":"146"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxVymEOgyAMBeALAT2SKbZTtgoEytTbLxiJ2Z_mve8ViTRhPAHv4F4lRTU-LFMOmWEEQ2mPkpAmCfEzCXoWLjDUdrW3Wl15Y8OHdgUqLaO4u5qMBZeCea1jecS1mJuXUFem_qhhFoY5FX4aoaLHyvYbeK-mnlV5gy7mEriuwzcef7AlasI_bXRd3g","theme":"particle","theme_token":null},"ajaxTrustedUrl":{"\/database\/export":true},"bigPipePlaceholderIds":{"callback=Drupal%5CCore%5CRender%5CElement%5CStatusMessages%3A%3ArenderMessages\u0026args%5B0%5D\u0026token=_HAdUpwWmet0TOTe2PSiJuMntExoshbm1kh2wQzzzAA":true},"data":{"extlink":{"extTarget":true,"extTargetAppendNewWindowLabel":"(opens in a new window)","extTargetNoOverride":false,"extNofollow":false,"extTitleNoOverride":false,"extNoreferrer":false,"extFollowNoOverride":false,"extClass":"ext","extLabel":"(link is external)","extImgClass":false,"extSubdomains":true,"extExclude":"(\\.gov.*?)","extInclude":"","extCssExclude":".footer-social-media, .social-share-button, .twitter-share-button","extCssInclude":"","extCssExplicit":"","extAlert":false,"extAlertText":"This link will take you to an external web site. We are not responsible for their content.","extHideIcons":false,"mailtoClass":"0","telClass":"","mailtoLabel":"(link sends email)","telLabel":"(link is a phone number)","extUseFontAwesome":false,"extIconPlacement":"append","extPreventOrphan":false,"extFaLinkClasses":"fa fa-external-link","extFaMailtoClasses":"fa fa-envelope-o","extAdditionalLinkClasses":"","extAdditionalMailtoClasses":"","extAdditionalTelClasses":"","extFaTelClasses":"fa fa-phone","whitelistedDomains":null,"extExcludeNoreferrer":""}},"views":{"ajax_path":"\/views\/ajax","ajaxViews":{"views_dom_id:a91e369a34a0b0c8121651c976dbf6e8745251b4871585c9f09fe6bcabf53144":{"view_name":"database","view_display_id":"block_6","view_args":"","view_path":"\/node\/881","view_base_path":"database\/export","view_dom_id":"a91e369a34a0b0c8121651c976dbf6e8745251b4871585c9f09fe6bcabf53144","pager_element":0,"viewsreference":{"compressed":"eJxdjrEKwzAMRP_Fc4e0eGl-pRShomsqcFRji5RQ8u-N8RDooOHu3gN9g7BzGG_3U4DxI0Gowl1tqr3NXGBO-6mv5GtGGFvJU-H8Cv-Ayj5fh_MxPBVJyHhuYg-L4nMABYtWfVt3Y4yXZndSHTMJUvtx2H4hST0K"}}}},"user":{"uid":0,"permissionsHash":"af5eece730f2d5aa6b0d43e1d564e85bd63161885787ef00214b14f2707a18ff"}}</script>
|
||
<script src="/themes/contrib/particle/apps/drupal/../../dist/app-drupal/assets/drupal-jquery.js?ss1xuy"></script>
|
||
<script src="/core/assets/vendor/once/once.min.js?v=1.0.1"></script>
|
||
<script src="/themes/contrib/particle/apps/drupal/../../node_modules/mark.js/dist/jquery.mark.js?ss1xuy"></script>
|
||
<script src="/core/misc/drupalSettingsLoader.js?v=10.4.1"></script>
|
||
<script src="/core/misc/drupal.js?v=10.4.1"></script>
|
||
<script src="/themes/contrib/particle/apps/drupal/includes/view-specific/database.js?ss1xuy"></script>
|
||
<script src="/core/misc/drupal.init.js?v=10.4.1"></script>
|
||
<script src="/core/assets/vendor/tabbable/index.umd.min.js?v=6.2.0"></script>
|
||
<script src="https://static.addtoany.com/menu/page.js" defer></script>
|
||
<script src="/modules/contrib/addtoany/js/addtoany.js?v=10.4.1"></script>
|
||
<script src="/core/misc/progress.js?v=10.4.1"></script>
|
||
<script src="/core/assets/vendor/loadjs/loadjs.min.js?v=4.3.0"></script>
|
||
<script src="/core/misc/debounce.js?v=10.4.1"></script>
|
||
<script src="/core/misc/announce.js?v=10.4.1"></script>
|
||
<script src="/core/misc/message.js?v=10.4.1"></script>
|
||
<script src="/core/misc/ajax.js?v=10.4.1"></script>
|
||
<script src="/themes/contrib/stable/js/ajax.js?v=10.4.1"></script>
|
||
<script src="/core/modules/big_pipe/js/big_pipe.js?v=10.4.1"></script>
|
||
<script src="/modules/contrib/extlink/js/extlink.js?v=10.4.1"></script>
|
||
<script src="/themes/contrib/particle/apps/drupal/funding.js?ss1xuy"></script>
|
||
<script src="/themes/contrib/particle/apps/drupal/../../dist/app-drupal/assets/app.js?ss1xuy"></script>
|
||
<script src="/themes/contrib/particle/apps/drupal/menus.js?ss1xuy"></script>
|
||
<script src="/core/misc/jquery.form.js?v=4.3.0"></script>
|
||
<script src="/core/modules/views/js/base.js?v=10.4.1"></script>
|
||
<script src="/core/modules/views/js/ajax_view.js?v=10.4.1"></script>
|
||
|
||
|
||
<script type="application/vnd.drupal-ajax" data-big-pipe-event="start"></script>
|
||
<script type="application/vnd.drupal-ajax" data-big-pipe-replacement-for-placeholder-with-id="callback=Drupal%5CCore%5CRender%5CElement%5CStatusMessages%3A%3ArenderMessages&args%5B0%5D&token=_HAdUpwWmet0TOTe2PSiJuMntExoshbm1kh2wQzzzAA">
|
||
[{"command":"insert","method":"replaceWith","selector":"[data-big-pipe-placeholder-id=\u0022callback=Drupal%5CCore%5CRender%5CElement%5CStatusMessages%3A%3ArenderMessages\u0026args%5B0%5D\u0026token=_HAdUpwWmet0TOTe2PSiJuMntExoshbm1kh2wQzzzAA\u0022]","data":"","settings":null}]
|
||
</script>
|
||
<script type="application/vnd.drupal-ajax" data-big-pipe-event="stop"></script>
|
||
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"4885254293","applicationID":"336795922","transactionName":"M1JQZkdWDRVYWkIPCQoYc1FBXgwIFn1EExYFW25cWlMGOnpWWBIUC1teV0drLQldXGAPAxN0XVxBRQwKVVxES1gSXldF","queueTime":15,"applicationTime":1985,"atts":"HxVHEA9MHkobWBRcHRlK","errorBeacon":"bam.nr-data.net","agent":""}</script></body>
|
||
</html>
|